BioNeutra Global Corp. said its normalized net income for the first quarter was 1 Canadian cents per share, a decline of 41.4% from 2 cents per share in the year-earlier period.
Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was C$553,760, a gain from C$135,690 in the year-earlier period.
The normalized profit margin fell to 10.4% from 11.7% in the year-earlier period.
Total revenue grew on an annual basis to C$5.3 million from C$1.2 million, and total operating expenses grew on an annual basis to C$4.5 million from C$829,650.
Reported net income decreased 12.9% from the prior-year period to C$403,750, or 1 cents per share, from C$463,790, or 8 cents per share.